Abstract
Background:Hepatic steatosis, including nonalcoholic fatty liver disease (NAFLD), is common among people with HIV (PWH). We present baseline steatosis prevalence and cardiometabolic characteristics among REPRIEVE substudy participants.Methods:REPRIEVE is an international, primary cardiovascular disease prevention, randomized, controlled trial of pitavastatin calcium vs. placebo among 7769 PWH ages 40-75years on antiretroviral therapy (ART) and with low-To-moderate cardiovascular risk. A subset of participants underwent noncontrast computed tomography, with hepatic steatosis defined as mean hepatic attenuation less than 40 HU or liver/spleen ratio less than 1.0, and NAFLD defined as steatosis in the absence of frequent alcohol use or viral hepatitis.Results:Of 687 evaluable persons, median age was 51years, BMI 27kg/m2, CD4+T-cell count 607 cells/μl; 17% natal female sex, 36% Black, 24% Hispanic, and 98% HIV-1 RNA less than 400copies/ml. Hepatic steatosis prevalence was 22% (149/687), and NAFLD 21% (96/466). Steatosis/NAFLD prevalence was higher in men and with older age, non-Black race, and higher BMI and waist circumference. Both were associated with BMI greater than 30kg/m2, metabolic syndrome components, higher atherosclerotic cardiovascular disease (ASCVD) risk score, HOMA-IR, LpPLA-2 and hs-CRP, and lower high-density lipoprotein cholesterol. Of HIV-specific/ART-specific characteristics, only history of an AIDS-defining illness was more common among persons with steatosis/NAFLD. After adjusting for age, sex and race/ethnicity, BMI greater than 30kg/m2, HOMA-IR greater than 2.0, Metabolic syndrome and each of its components were associated with NAFLD prevalence.Conclusion:In this cohort with controlled HIV and low-To-moderate cardiovascular risk, hepatic steatosis and NAFLD were common and associated with clinically relevant metabolic and inflammatory disturbances but not current HIV-related or ART-related factors.
Author supplied keywords
Cite
CITATION STYLE
Lake, J. E., Taron, J., Ribaudo, H. J., Leon-Cruz, J., Utay, N. S., Swaminathan, S., … Fichtenbaum, C. J. (2023). Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV. AIDS, 37(14), 2149–2159. https://doi.org/10.1097/QAD.0000000000003671
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.